Fuji Chemical Industry Co., Ltd.

October 2009

Headline	Introducing Fujicalin's product information site
Contents	Fuji Chemical Industry has launched a dedicated website for Fujicalin®. This site aims to provide readers with an abundant resource of product information in a visually appealing format. Access Fujicalin®'s characteristics, functions and examples online to support your formulation development with this unique product. Furthermore, Fuji will regularly update this site with technical newsletters as well as any event information. The website can be accessed at, www.fujicalin.com Fujicalin® is a totally synthetic dibasic calcium phosphate anhydrous (DCPA). It is an ideal excipient for direct compression formulations, especially involving difficult-to-compress materials like oily actives. It can also be used to assist flow, reduce tablet weight variation and improve content uniformity.

Headline

Introducing Fujicalin's product information site

Contents

Fuji Chemical Industry has launched a dedicated website for Fujicalin®. This site aims to provide readers with an abundant resource of product information in a visually appealing format. Access Fujicalin®'s characteristics, functions and examples online to support your formulation development with this unique product. Furthermore, Fuji will regularly update this site with technical newsletters as well as any event information.

The website can be accessed at,

www.fujicalin.com

Fujicalin® is a totally synthetic dibasic calcium phosphate anhydrous (DCPA). It is an ideal excipient for direct compression formulations, especially involving difficult-to-compress materials like oily actives. It can also be used to assist flow, reduce tablet weight variation and improve content uniformity.

Headline	"Excipients for oral disintegrating tablets Accelerating global expansion Adopted in Japan and then in the United States" Kagaku Kogyou Nippo reported
Contents	Translated from the original article published in Kagaku Kogyo Nippo(Chemical Industry Daily) 17 September 2009 Fuji Chemical Industry Co., Ltd. (based in Nakaniikawa-gun, Toyama; President: Mitsunori Nishida) has been promoting the increasing global use of excipients in oral disintegrating tablets (ODTs). In Japan, excipients have just been successively adopted for generic and new drugs. Abroad, they will be adopted by a pharmaceutical maker in the United States later this year at the earliest; their sale will also be promoted in the European market. Concurrently, to further drive the expansion of domestic and foreign markets for excipients, Fuji intends to expand the applications of the excipients by developing applications as pharmaceutical core particles that can adsorb and release various drugs, as well as promoting the development of new products with higher functionality. Actively promoting application development The main business of Fuji Chemical Industry Co., Ltd. is contract manufacturing of bulk pharmaceutical products and production and sales of functional excipients. The functional excipients include Neusilin, which is used as an antacid and whose main ingredients are magnesium aluminometasilicate and magnesium aluminosilicate, and Fujicalin, which comprises minute primary particles with excellent moldability and whose main ingredient is anhydrous dibasic calcium phosphate. Fuji intends to expand the global market for F-MELT. F-MELT is an excipient for ODTs and is produced from carbohydrates, disintegrants, and inorganic excipients by a special spray-drying technique; it has excellent moldability and disintegration properties, which do not conflict with each other. F-MELT comprises spherical particles with excellent flowability that disintegrate within 30 seconds; thus, it can be used for direct compression manufacturing of ODTs by simply blending active pharmaceutical ingredients and lubricants. These features contribute to its successful adoption by domestic and foreign manufacturers. F-MELT has just been adopted for generic and new drugs by domestic makers, and additionally, it will be adopted by a U. S. pharmaceutical maker later this year or at the beginning of next year. Since F-MELT involves the use of pharmaceutical additives meeting the pharmacopoeia of major countries, Fuji intends to market it actively to European pharmaceutical companies. Moreover, Fuji will expand the applications of the excipient. The mean particle size is reduced by applying conventional techniques for Neusilin and Fujicalin. Fuji also advances the development of new products that mask the unpleasant taste in tablets and in which the swelling that causes cracking of coating on pharmaceutical ingredients is eliminated. In addition, by exploiting its excellent water and oil absorption capability, Fuji aims to realize its application as pharmaceutical core particles that can adsorb and release various drugs. Fuji accelerates market expansion both within and outside Japan by continuously improving the functions of the functional excipients and increasing their utility.

Headline

"Excipients for oral disintegrating tablets Accelerating global expansion Adopted in Japan and then in the United States" Kagaku Kogyou Nippo reported

Contents

Translated from the original article published in Kagaku Kogyo Nippo(Chemical Industry Daily) 17 September 2009

Fuji Chemical Industry Co., Ltd. (based in Nakaniikawa-gun, Toyama; President: Mitsunori Nishida) has been promoting the increasing global use of excipients in oral disintegrating tablets (ODTs). In Japan, excipients have just been successively adopted for generic and new drugs. Abroad, they will be adopted by a pharmaceutical maker in the United States later this year at the earliest; their sale will also be promoted in the European market. Concurrently, to further drive the expansion of domestic and foreign markets for excipients, Fuji intends to expand the applications of the excipients by developing applications as pharmaceutical core particles that can adsorb and release various drugs, as well as promoting the development of new products with higher functionality.

Actively promoting application development

The main business of Fuji Chemical Industry Co., Ltd. is contract manufacturing of bulk pharmaceutical products and production and sales of functional excipients. The functional excipients include Neusilin, which is used as an antacid and whose main ingredients are magnesium aluminometasilicate and magnesium aluminosilicate, and Fujicalin, which comprises minute primary particles with excellent moldability and whose main ingredient is anhydrous dibasic calcium phosphate.

Fuji intends to expand the global market for F-MELT. F-MELT is an excipient for ODTs and is produced from carbohydrates, disintegrants, and inorganic excipients by a special spray-drying technique; it has excellent moldability and disintegration properties, which do not conflict with each other. F-MELT comprises spherical particles with excellent flowability that disintegrate within 30 seconds; thus, it can be used for direct compression manufacturing of ODTs by simply blending active pharmaceutical ingredients and lubricants.
These features contribute to its successful adoption by domestic and foreign manufacturers. F-MELT has just been adopted for generic and new drugs by domestic makers, and additionally, it will be adopted by a U. S. pharmaceutical maker later this year or at the beginning of next year. Since F-MELT involves the use of pharmaceutical additives meeting the pharmacopoeia of major countries, Fuji intends to market it actively to European pharmaceutical companies.
Moreover, Fuji will expand the applications of the excipient. The mean particle size is reduced by applying conventional techniques for Neusilin and Fujicalin. Fuji also advances the development of new products that mask the unpleasant taste in tablets and in which the swelling that causes cracking of coating on pharmaceutical ingredients is eliminated. In addition, by exploiting its excellent water and oil absorption capability, Fuji aims to realize its application as pharmaceutical core particles that can adsorb and release various drugs.
Fuji accelerates market expansion both within and outside Japan by continuously improving the functions of the functional excipients and increasing their utility.